Daily Archives: November 29, 2018

Canadian Tech Company B-Temia Enters Into a $6.9M USD US Army / Lockheed Martin Agreement

B-Temia and Lockheed Martin Team Up to Optimize ONYX™ Exoskeleton

QUÉBEC CITY, Nov. 29, 2018 (GLOBE NEWSWIRE) — B-Temia, a Canadian robotics tech company and leader in the human mobility market, announced its engagement in a major agreement with U.S. Army Natick Soldier Research, Development and Engineering Center (NSRDEC) with its partner Lockheed Martin (NYSE: LMT), appointed as the prime contractor.  At a total value of $6.9M USD, the agreement is for the optimization of the of the ONYXTM exoskeleton, the military version of the B-Temia’s DermoskeletonTM technology, for field trials with military operators.  ONYXTM is a brand owned by Lockheed Martin under the B-Temia EnabledTM co-branding.

“Our involvement in this major agreement is the result of 2 years of successful teamwork with our defence & security partner Lockheed Martin and our special advisor Ms. Rita Vazquez-Torres (New Stone Soup Inc.). This work is another key event in our growth phase and provides us the ability to significantly increase our technological edge with our DermoskeletonTM technology. B-Temia is now expanding, not only around the world, but also in the military market”, stated Mr. Stephane Bedard, CEO of B-Temia Inc.  “This NSRDEC / Lockheed Martin agreement is another acknowledgement from the market on the value of our DermoskeletonTM. We are proud and thrilled to materialize our vision of protecting the biomechanical health of military personnel”, added Mr. Bedard.

ONYX is a powered, lower-body exoskeleton with artificial intelligence (AI) technology that augments human strength and endurance.  ONYX counteracts overstress on the lower back and legs. Using electro-mechanical knee actuators, a suite of sensors, and an AI computer, ONYX learns user movements and delivers the right torque at the right time to assist with walking up steep inclines, lifting or dragging heavy loads.

“Innovative human/machine technologies like ONYX can improve human performance, decrease injury and reduce fatigue to help soldiers accomplish physically demanding tasks,” said Keith Maxwell, exoskeleton technologies program manager at Lockheed Martin’s Missiles and Fire Control division. “This award brings us one step closer to equipping future forces with advanced exoskeleton capabilities.”

“We are very pleased to see Quebec-based B-Temia Inc. team up with Lockheed Martin to optimize the ONYX exoskeleton for the US Army. Innovation in robotics is a key initiative for Lockheed Martin and it is great to see a Canadian small-medium enterprise play such an important contributing role in providing solutions,” said Charles Bouchard, Chief Executive of Lockheed Martin Canada.

About B-Temia
Founded in 2010, B-Temia Inc. is an innovative Canadian robotics technology company that develops and markets cutting-edge products for the growing market of human augmentation systems. B-Temia operates through two wholly-owned subsidiaries, B-Temia Inc. and B-Temia USA Inc., in the medical, industrial and military fields. B-Temia owns a patented technology called Dermoskeleton™ that restores, maintains or enhances the mobility of users.  For more information, please visit: www.b-temia.com

About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 100,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services. This year the company received three Edison Awards for ground-breaking innovations in autonomy, satellite technology and directed energy.  For more information, please visit: www.lockheedmartin.com

About New Stone Soup
NSS VT LLC is a cross-government technology strategy consulting firm, specializing in networking across government cultures, and creating solid partnerships between government agencies, industry and academia. We specialize in strategic analysis of goals and objectives, and designing innovative teaming concepts to explore and ultimately transition disruptive technologies to the Military, Homeland Security, Public Safety and Commercial market. NSS has been operating for two years, with over 25 years of combined Military, Homeland Security and Public Safety Science and technology experience.  For more information, please visit: http://newstonesoupvt.com/

Information – B-Temia

Source: Media:
B-TEMIA Inc. Pamela Borges
4780, St-Félix Street, Suite 105 VP Market Access & External Affairs
St-Augustin (Québec) G3A 2J9 Phone: (416) 520-5270
www.b-temia.com | www.keeogo.com E-mail: pamela.borges@b-temia.com
Phone: (418) 653-1010
E-mail: info@b-temia.com

Information – Lockheed Martin

Media:
Anthony Mickle
5600 Sand Lake Road
Orlando, FL 32819
Phone: (407) 619-8676
E-mail: Anthony.b.mickle@lmco.com
www.lockheedmartin.com/onyx

Two photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/b3d3c970-f282-4e2d-b10a-789a20e885b0
http://www.globenewswire.com/NewsRoom/AttachmentNg/e394b5eb-dc65-4aeb-807e-ce5e73fa0878

Teledyne image sensors power cameras onboard NASA’s InSight Mission to Mars

Color sensors from Teledyne’s world-class semiconductor foundry will capture all images returned to Earth from Mars

WATERLOO, Ontario, Nov. 29, 2018 (GLOBE NEWSWIRE) — Teledyne DALSA, a Teledyne Technologies [NYSE: TDY] company and global leader in digital imaging, is pleased to participate in NASA’s InSight Mission to Mars by providing color CCD image sensors for both the Instrument Deployment Camera (IDC) and the Instrument Context Camera.

Teledyne is pleased to have partnered with Jet Propulsion Labs (JPL) to deliver the color image sensors to power the InSight mission. The camera on the Lander’s arm will provide 3D color views of the landing site, instrument placement, and activities to inform engineers and scientists of the best spots for the seismometer and heat flow probe to gather measurements from the interior of Mars._mars.nasa.gov_insight-raw-images_surface_sol_0001_idc_D000M0001_596622265EDR_F0000_0463M_

Teledyne image sensors are not new to Mars. As recently as 2012, and in an earlier partnership with JPL, the company provided twelve black and white CCD image sensors to power the Mars Rover “Curiosity”. The Teledyne Imaging Space & Defense group, comprised of Teledyne DALSA, Teledyne e2v and Teledyne Imaging & Scientific, are renowned for their delivery of innovative sensing and camera solutions for the exploration of space, with capabilities across the spectrum, from infrared to x-ray imaging.

“We are pleased to join our partner JPL in this fact-finding mission,” commented Edwin Roks, Group President, Teledyne Digital Imaging. “We expect this mission to tell us much about the origins of Mars, and indeed, the formation of our own planet.”

While the InSight lander began its surface operations immediately, science data collection will begin rougly 10 weeks after landing. Teledyne’s image sensors will play a major role in helping scientists and engineers decide where to place the very specialized instruments to inform the best results of the study of Mars’ interior.

https://mars.nasa.gov/insight/timeline/surface-operations/

About Teledyne DALSA
Teledyne DALSA is part fo the Teledyne Imaging group, and an international leader in high performance digital imaging and semiconductors with approximately 1,000 employees worldwide.

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum and decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

All trademarks are registered by their respective companies.
Teledyne DALSA reserves the right to make changes at any time without notice.

Media Contact:
Geralyn Miller, Senior Manager, Global Media Relations
Teledyne Imaging
t: +1-519-886-6001 x2187
geralyn.miller@teledyne.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/266b885d-7dbb-44c9-bb47-da525889ac82

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

Invivoscribe also Receives National Reimbursement for CDx Assay in Japan

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) — Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate), for treatment of FLT3 positive refractory/relapse acute myeloid leukemia (AML) patients in the US.  Further, the Japanese MHLW has confirmed national reimbursement for the LeukoStrat CDx FLT3 Mutation Assay in Japan.

Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Astellas as the companion diagnostic to predict patient responses to Astellas Pharma’s AML drug XOSPATA (gilteritinib fumarate).

This approval complements Invivoscribe’s prior regulatory approvals of this LeukoStrat CDx FLT3 Mutation Assay as the companion diagnostic for RYDAPT (midostaurin) for Novartis (United States and Europe), and XOSPATA (gilteritinib fumarate) for Astellas (Japan). This CDx was also recently submitted to the PMDA in Japan and the US FDA as the CDx for predicting response to the Daiichi Sankyo drug, VANFLYTA (quizartinib hydrochloride).

This milestone further establishes the LeukoStrat CDx FLT3 Mutation Assay as the international gold standard for comprehensive FLT3 assessment for critically ill AML patients as this CDx identifies both ITD and TKD mutations (including large internal tandem duplications), is available worldwide, and generates standardized signal ratios for both ITD and TKD mutations.

“Invivoscribe welcomes opportunities to use our Streamlined CDx™ program to partner with global pharmaceutical companies interested in developing and commercializing companion diagnostics, whether their therapies are targeting hematologic diseases or solid tumors,” said Jeffrey Miller, Invivoscribe’s CSO and CEO.

About the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia. This globally standardized test includes software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to both gilteritinib fumarate and midostaurin. This extensively validated assay helps standardize the detection of genetic mutations in the FLT3 gene as one of the most important driver mutations in Acute Myeloid Leukemia (AML).

The LeukoStrat test is available as a test menu service through the Invivoscribe subsidiaries, LabPMM LLC (San Diego, CA, US), LabPMM GmbH (Martinsried, Germany) and LabPMM GK (Kawasaki City, Japan). LeukoStrat CDx FLT3 Mutation Assay kits are currently distributed in Europe, will be available in Japan in 2018, and are planned for distribution in the United States, and China in the future.

About Invivoscribe
Invivoscribe is a privately held biotechnology company dedicated to Improving Lives with Precision Diagnostics. For nearly twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.

For additional information please contact Invivoscribe at support@invivoscribe.com or visit www.invivoscribe.com.

CNH Industrial announces voting results of Extraordinary General Meeting

London, November 29, 2018

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announced today that the Extraordinary General Meeting of shareholders (“EGM”) held today in Amsterdam, the Netherlands, elected Hubertus M. Mühlhäuser and Suzanne Heywood as executive directors of the Company.

Details of the resolutions submitted to the EGM and approved today are available on the Company’s website (www.cnhindustrial.com).

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

Media contact:

CNH Industrial Corporate Communications
Tel: +44 (0)20 776 0346
Email: mediarelations@cnhind.com

Attachment